Matrifen (Fentanyl)

Fentanyl acts as a potent mu‑opioid receptor agonist in the central nervous system. By activating these receptors, it inhibits the transmission of pain signals and alters the perception of pain, resulting in strong analgesic effects. Its high lipophilicity allows efficient absorption through the skin when delivered via a patch.

The specific dose and patch strength are determined by the prescribing clinician based on the patient’s opioid tolerance, pain severity, and clinical response. Dosing decisions are individualized, and the prescriber will select the appropriate patch strength and replacement interval for each patient.

The safety of fentanyl patches during pregnancy and lactation has not been fully established. Because opioids can cross the placenta and enter breast milk, use is generally avoided unless the potential benefit justifies the potential risk. Clinicians should discuss risks and alternatives with the patient.

To request Matrifen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with oral morphine, the fentanyl patch offers continuous, steady‑state plasma levels without the peaks and troughs associated with oral dosing. It is also more potent on a per‑microgram basis, allowing once‑weekly application, which can improve adherence for patients who have difficulty taking multiple oral doses.

Matrifen patches should be stored at room temperature, below 25 °C, in their original sealed packaging. Keep them away from moisture, direct sunlight, and heat sources. Do not expose the patches to extreme temperatures, and discard any patch that appears damaged or discolored.

The patch is applied to a clean, dry, hair‑free area of intact skin on the upper torso, upper arm, or thigh. Press firmly for about 30 seconds to ensure good contact. The patch remains in place for the prescribed duration (usually seven days) and is then removed and disposed of safely.

The most critical risks include respiratory depression, which can be life‑threatening, severe hypotension, and the potential for opioid dependence or withdrawal if the patch is stopped abruptly. Patients should be monitored closely for signs of shallow breathing, excessive sedation, or sudden drops in blood pressure.

Matrifen is contraindicated in patients with known hypersensitivity to fentanyl or any patch components, those with severe respiratory insufficiency, acute or severe asthma, and individuals who are not opioid‑tolerant. It should also be avoided in patients with significant head injuries or increased intracranial pressure.